SIERRA ONCOLOGY, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances
SIERRA ONCOLOGY, INC. reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances of $25.00 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-03.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues · last filed 2020-03-03
- SIERRA ONCOLOGY, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2019 was $25.00M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 12 month |
|---|---|
| 2019-12-31 | $25.00M 10-K · filed 2020-03-03 |